Long-term biochemical control of prostate cancer after standard or hyper-fractionation: evidence for different outcomes between low-intermediate and high risk patients.

Long-term biochemical control of prostate cancer after standard or hyper-fractionation: evidence for different outcomes between low-intermediate and high risk patients.